Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Add as a preferred source on Google
LEXINGTON, Mass., April 24, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2017 first quarter financial and operational results after the market closes on Tuesday, May 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 2, 2017, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.
Media Contact: Matthew McKillip, T2 Biosystems [email protected] 518-577-3466 Investor Contact: Tucker Elcock, Teneo Strategy [email protected] 212-886-9319
